JP2020183440A5 - - Google Patents

Download PDF

Info

Publication number
JP2020183440A5
JP2020183440A5 JP2020127877A JP2020127877A JP2020183440A5 JP 2020183440 A5 JP2020183440 A5 JP 2020183440A5 JP 2020127877 A JP2020127877 A JP 2020127877A JP 2020127877 A JP2020127877 A JP 2020127877A JP 2020183440 A5 JP2020183440 A5 JP 2020183440A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
dose
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020127877A
Other languages
English (en)
Japanese (ja)
Other versions
JP7225167B2 (ja
JP2020183440A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020183440A publication Critical patent/JP2020183440A/ja
Publication of JP2020183440A5 publication Critical patent/JP2020183440A5/ja
Application granted granted Critical
Publication of JP7225167B2 publication Critical patent/JP7225167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020127877A 2012-06-01 2020-07-29 コエンザイムq10を用いた固形腫瘍の治療 Active JP7225167B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654245P 2012-06-01 2012-06-01
US61/654,245 2012-06-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018109093A Division JP2018168164A (ja) 2012-06-01 2018-06-07 コエンザイムq10を用いた固形腫瘍の治療

Publications (3)

Publication Number Publication Date
JP2020183440A JP2020183440A (ja) 2020-11-12
JP2020183440A5 true JP2020183440A5 (cg-RX-API-DMAC7.html) 2020-12-24
JP7225167B2 JP7225167B2 (ja) 2023-02-20

Family

ID=49673946

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015515272A Active JP6352905B2 (ja) 2012-06-01 2013-05-31 コエンザイムq10を用いた固形腫瘍の治療
JP2018109093A Withdrawn JP2018168164A (ja) 2012-06-01 2018-06-07 コエンザイムq10を用いた固形腫瘍の治療
JP2020127877A Active JP7225167B2 (ja) 2012-06-01 2020-07-29 コエンザイムq10を用いた固形腫瘍の治療

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015515272A Active JP6352905B2 (ja) 2012-06-01 2013-05-31 コエンザイムq10を用いた固形腫瘍の治療
JP2018109093A Withdrawn JP2018168164A (ja) 2012-06-01 2018-06-07 コエンザイムq10を用いた固形腫瘍の治療

Country Status (16)

Country Link
US (3) US20140017317A1 (cg-RX-API-DMAC7.html)
EP (1) EP2854528B8 (cg-RX-API-DMAC7.html)
JP (3) JP6352905B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200118233A (cg-RX-API-DMAC7.html)
CN (1) CN104507308A (cg-RX-API-DMAC7.html)
AU (2) AU2013267166A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014029954A2 (cg-RX-API-DMAC7.html)
CA (2) CA3090268A1 (cg-RX-API-DMAC7.html)
EA (1) EA032345B1 (cg-RX-API-DMAC7.html)
ES (1) ES2761449T3 (cg-RX-API-DMAC7.html)
IL (1) IL236008B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN10734A (cg-RX-API-DMAC7.html)
MX (2) MX369768B (cg-RX-API-DMAC7.html)
NZ (1) NZ702369A (cg-RX-API-DMAC7.html)
SG (1) SG11201407880QA (cg-RX-API-DMAC7.html)
WO (1) WO2013181639A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
US20140017317A1 (en) * 2012-06-01 2014-01-16 Niven Rajin Narain Methods of treatment of solid tumors using coenzyme q10
BR112015025424A2 (pt) * 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
MX381399B (es) 2013-09-04 2025-03-12 Berg Llc Formulaciones de coenzima q10 y métodos de uso.
US9996463B2 (en) * 2015-11-10 2018-06-12 International Business Machines Corporation Selection and placement of volumes in a storage system using stripes
WO2017087576A1 (en) * 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20170255565A1 (en) * 2016-03-02 2017-09-07 Intel Corporation Method and apparatus for providing a contiguously addressable memory region by remapping an address space
WO2018005412A1 (en) * 2016-06-28 2018-01-04 Tien Yang Der Chemoprotective/chemoactive nanodroplets and methods of use thereof
CA3063916A1 (en) * 2017-05-17 2018-11-22 Berg Llc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
CA3239264A1 (en) * 2021-12-01 2023-06-08 Gambro Lundia Ab New dialysis fluid
WO2025087731A1 (en) * 2023-10-24 2025-05-01 Gambro Lundia Ab Compositions comprising insulin and ketones bodies to treat cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
WO2005048925A2 (en) * 2003-11-14 2005-06-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
HRP20130459T1 (en) 2004-01-22 2013-06-30 University Of Miami Topical co-enzyme q10 formulations and methods of use
WO2008069276A1 (ja) * 2006-12-06 2008-06-12 Kaneka Corporation 癌治療剤および発癌抑制剤
US8454945B2 (en) 2007-03-22 2013-06-04 Berg Pharma Llc Topical formulations having enhanced bioavailability
WO2009064738A2 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
GB0913193D0 (en) 2009-07-29 2009-09-02 Johnson Matthey Plc Deoxygenation process
BR112012022916B1 (pt) * 2010-03-12 2021-11-09 Berg Llc Formulações intravenosas de coenzima q10 (coq10), bem como método de preparação e uso da mesma
US20140239525A1 (en) 2011-06-17 2014-08-28 Board Of Regents, University Of Texas System Inhalable pharmaceutical compositions
US20140017317A1 (en) * 2012-06-01 2014-01-16 Niven Rajin Narain Methods of treatment of solid tumors using coenzyme q10

Similar Documents

Publication Publication Date Title
Böttger et al. High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer
JP2015518056A5 (cg-RX-API-DMAC7.html)
EP2488178B1 (en) Combinations of a pi3k inhibitor and a mek inhibitor
JP6648040B2 (ja) がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
EP2786756B1 (en) Combination therapy with a topoisomerase inhibitor
Droz et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial
US12083136B2 (en) Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof
TWI818954B (zh) 三取代之苯并三唑衍生物的使用方法
JP2014513089A (ja) アフリバーセプト、フォリン酸、5−フルオロウラシル(5−fu)及びイリノセタン(フォルフィリ)を含む組成物
CN1429114A (zh) 联合化学疗法
Wolff et al. A double‐blind, randomized, placebo‐controlled, phase 2 study of maintenance enzastaurin with 5‐fluorouracil/leucovorin plus bevacizumab after first‐line therapy for metastatic colorectal cancer
Gatzemeier et al. Tirapazamine-cisplatin: the synergy
Mountzios et al. Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non‐Platinum‐Containing Regimens, and Molecular Targeted Agents
JP2024515215A5 (cg-RX-API-DMAC7.html)
US20090281105A1 (en) Radiotherapy enhancer
WO2020254299A1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
TW201628608A (zh) 治療或緩解高齡或末期癌症患者用之醫藥組合物
Said et al. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver
Kudo Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail?
Xue et al. Anti-angiogenesis treatment in a patient with appendix metastasis of small cell lung cancer: A case report
Liu et al. Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice
Schwartz et al. The addition of chloroquine and metformine to Metabloc induces a rapid drop of tumor markers in advanced carcinoma
AU2006231809A1 (en) Potentiator for radiation therapy comprising pyridine derivative as active ingredient
EP2817010B1 (en) Compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
CN101155782A (zh) 以吡啶衍生物为有效成分的放射线治疗增强剂